Cationic amphiphilic peptides with cancer-selective toxicity.

[1]  Ülo Langel,et al.  Design of a Tumor Homing Cell-Penetrating Peptide for Drug Delivery , 2009, International Journal of Peptide Research and Therapeutics.

[2]  S. C. Kim,et al.  Mechanism of anticancer activity of buforin IIb, a histone H2A-derived peptide. , 2008, Cancer letters.

[3]  Y. Shai,et al.  Antimicrobial lipopolypeptides composed of palmitoyl Di- and tricationic peptides: in vitro and in vivo activities, self-assembly to nanostructures, and a plausible mode of action. , 2008, Biochemistry.

[4]  A. Rinaldi,et al.  Antimicrobial peptides: natural templates for synthetic membrane-active compounds , 2008, Cellular and Molecular Life Sciences.

[5]  J. Svendsen,et al.  Synthetic antimicrobial peptidomimetics with therapeutic potential. , 2008, Journal of medicinal chemistry.

[6]  B. Brandsdal,et al.  Antimicrobial peptides with stability toward tryptic degradation. , 2008, Biochemistry.

[7]  D. Hoskin,et al.  Studies on anticancer activities of antimicrobial peptides. , 2008, Biochimica et biophysica acta.

[8]  Michael J Sailor,et al.  Biomimetic amplification of nanoparticle homing to tumors , 2007, Proceedings of the National Academy of Sciences.

[9]  R. Hancock,et al.  Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies , 2006, Nature Biotechnology.

[10]  R. Pérez-Tomás,et al.  Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. , 2006, Current medicinal chemistry.

[11]  S. Ye,et al.  Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents. , 2006, The American journal of pathology.

[12]  A. Corti,et al.  Synergistic Antitumor Activity of Cisplatin, Paclitaxel, and Gemcitabine with Tumor Vasculature-Targeted Tumor Necrosis Factor-α , 2006, Clinical Cancer Research.

[13]  B. Bernard,et al.  Anticancer activity of targeted proapoptotic peptides. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  E Ruoslahti,et al.  Vascular homing peptides with cell-penetrating properties. , 2005, Current pharmaceutical design.

[15]  Y. Shai,et al.  Conjugation of fatty acids with different lengths modulates the antibacterial and antifungal activity of a cationic biologically inactive peptide. , 2005, The Biochemical journal.

[16]  Z. Figaszewski,et al.  Changes in electric charge and phospholipids composition in human colorectal cancer cells , 2005, Molecular and Cellular Biochemistry.

[17]  Y. Shai,et al.  pH-dependent antifungal lipopeptides and their plausible mode of action. , 2005, Biochemistry.

[18]  Lurong Zhang,et al.  Tachyplesin activates the classic complement pathway to kill tumor cells. , 2005, Cancer research.

[19]  Y. Shai,et al.  Host defense peptides as new weapons in cancer treatment , 2005, Cellular and Molecular Life Sciences CMLS.

[20]  Robert E W Hancock,et al.  A re-evaluation of the role of host defence peptides in mammalian immunity. , 2005, Current protein & peptide science.

[21]  A. Corti,et al.  Crucial Role for Interferon γ in the Synergism between Tumor Vasculature-Targeted Tumor Necrosis Factor α (NGR-TNF) and Doxorubicin , 2004, Cancer Research.

[22]  C. Leuschner,et al.  Membrane disrupting lytic peptides for cancer treatments. , 2004, Current pharmaceutical design.

[23]  C. Pidgeon,et al.  Intestinal Peptide Transport Systems and Oral Drug Availability , 1999, Pharmaceutical Research.

[24]  H. P. Fell,et al.  Identification of serum components that inhibit the tumoricidal activity of amphiphilic alpha helical peptides , 2004, Cancer Chemotherapy and Pharmacology.

[25]  Mouldy Sioud,et al.  Selective targeting of cancer cells using synthetic peptides. , 2003, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[26]  Niv Papo,et al.  New lytic peptides based on the D,L-amphipathic helix motif preferentially kill tumor cells compared to normal cells. , 2003, Biochemistry.

[27]  Niv Papo,et al.  A Novel Lytic Peptide Composed of dl-Amino Acids Selectively Kills Cancer Cells in Culture and in Mice* , 2003, Journal of Biological Chemistry.

[28]  Dong-Kuk Lee,et al.  Mechanism of lipid bilayer disruption by the human antimicrobial peptide, LL-37. , 2003, Biochemistry.

[29]  J. Svendsen,et al.  The pharmacophore of short cationic antibacterial peptides. , 2003, Journal of medicinal chemistry.

[30]  Qing-Rong Liu,et al.  Effects of tachyplesin on proliferation and differentiation of human hepatocellular carcinoma SMMC-7721 cells. , 2002, World journal of gastroenterology.

[31]  P. Bulet,et al.  Antiviral and antitumor peptides from insects , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Hueih Min Chen,et al.  The combined effects of antibacterial peptide cecropin A and anti-cancer agents on leukemia cells. , 2002, Anticancer research.

[33]  S. Dowdy,et al.  Protein transduction technology. , 2002, Current opinion in biotechnology.

[34]  M. Zasloff.  Antimicrobial peptides of multicellular organisms , 2002, Nature.

[35]  J. Mai,et al.  A proapoptotic peptide for the treatment of solid tumors. , 2001, Cancer research.

[36]  G. Kroemer,et al.  A Role of the Mitochondrial Apoptosis-Inducing Factor in Granulysin-Induced Apoptosis1 , 2001, The Journal of Immunology.

[37]  Y. Chen,et al.  RGD-Tachyplesin inhibits tumor growth. , 2001, Cancer research.

[38]  S. White,et al.  Structure, location, and lipid perturbations of melittin at the membrane interface. , 2001, Biophysical journal.

[39]  E. Ikonen,et al.  How cells handle cholesterol. , 2000, Science.

[40]  S. Eom,et al.  CRAMP analogues having potent antibiotic activity against bacterial, fungal, and tumor cells without hemolytic activity. , 2000, Biochemical and biophysical research communications.

[41]  John Calvin Reed,et al.  Cytochrome c release and apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3. , 2000, Science.

[42]  C. B. Park,et al.  Structure-activity analysis of buforin II, a histone H2A-derived antimicrobial peptide: the proline hinge is responsible for the cell-penetrating ability of buforin II. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[43]  C. Yu,et al.  Conformational study of a custom antibacterial peptide cecropin B1: implications of the lytic activity. , 2000, Biochimica et biophysica acta.

[44]  W. Earnshaw,et al.  Induction of apoptosis by cancer chemotherapy. , 2000, Experimental cell research.

[45]  K. Gelmon,et al.  In vitro characterization of the anticancer activity of membrane-active cationic peptides. I. Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin against wild-type and p-glycoprotein over-expressing tumor cell lines. , 2000, Anti-cancer drug design.

[46]  Y. Shai,et al.  Androctonin, a hydrophilic disulphide-bridged non-haemolytic anti-microbial peptide: a plausible mode of action. , 2000, The Biochemical journal.

[47]  Y. Shai,et al.  Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by alpha-helical antimicrobial and cell non-selective membrane-lytic peptides. , 1999, Biochimica et biophysica acta.

[48]  S. Chan,et al.  Membrane lysis by the antibacterial peptides cecropins B1 and B3: A spin-label electron spin resonance study on phospholipid bilayers. , 1999, Biophysical journal.

[49]  S. Saini,et al.  Melittin activates endogenous phospholipase D during cytolysis of human monocytic leukemia cells. , 1999, Toxicon : official journal of the International Society on Toxinology.

[50]  Erkki Ruoslahti,et al.  Anti-cancer activity of targeted pro-apoptotic peptides , 1999, Nature Medicine.

[51]  S. Chan,et al.  Enhancement of the cytolytic effect of anti-bacterial cecropin by the microvilli of cancer cells. , 1998, Anticancer research.

[52]  R Pasqualini,et al.  Chemotherapy targeted to tumor vasculature. , 1998, Current opinion in oncology.

[53]  H. Friess,et al.  The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer. , 1998, The Journal of clinical investigation.

[54]  S. Cory,et al.  Matters of life and death: programmed cell death at Cold Spring Harbor. , 1998, Biochimica et biophysica acta.

[55]  R. Holle,et al.  Antimicrobial peptides melittin and cecropin inhibit replication of human immunodeficiency virus 1 by suppressing viral gene expression. , 1998, The Journal of general virology.

[56]  R. Hancock,et al.  Cationic peptides: a new source of antibiotics. , 1998, Trends in biotechnology.

[57]  Brian Salmons,et al.  Expression of antimicrobial peptides has an antitumour effect in human cells. , 1998, Biochemical and biophysical research communications.

[58]  Y. Shai,et al.  Mode of action of linear amphipathic α-helical antimicrobial peptides , 1998 .

[59]  M. Hollingsworth,et al.  Oligosaccharides Expressed on MUC1 Produced by Pancreatic and Colon Tumor Cell Lines* , 1997, The Journal of Biological Chemistry.

[60]  P. Axelsen,et al.  The concentration-dependent membrane activity of cecropin A. , 1997, Biochemistry.

[61]  S. Chan,et al.  Effects of the anti-bacterial peptide cecropin B and its analogs, cecropins B-1 and B-2, on liposomes, bacteria, and cancer cells. , 1997, Biochimica et biophysica acta.

[62]  A. Schroit,et al.  Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. , 1997, Blood.

[63]  W. Yoon,et al.  Effect of O-glycosylated mucin on invasion and metastasis of HM7 human colon cancer cells. , 1996, Biochemical and biophysical research communications.

[64]  J. Styles,et al.  Chemoprevention of Breast Cancer by Tamoxifen: Risks and Opportunities , 2000, Toxicology letters.

[65]  R. B. Merrifield,et al.  Retro and retroenantio analogs of cecropin-melittin hybrids. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[66]  M. Zasloff,et al.  Anticancer efficacy of Magainin2 and analogue peptides. , 1993, Cancer research.

[67]  Sreenath V. Sharma,et al.  Melittin-induced hyperactivation of phospholipase A2 activity and calcium influx in ras-transformed cells. , 1993, Oncogene.

[68]  H. Aoyagi,et al.  Conformation of tachyplesin I from Tachypleus tridentatus when interacting with lipid matrices. , 1992, Biochemistry.

[69]  A. Gazdar,et al.  Antitumor activity of magainin analogues against human lung cancer cell lines. , 1992, Cancer research.

[70]  S. Sharma.  Melittin resistance: a counterselection for ras transformation. , 1992, Oncogene.

[71]  L. Tamm,et al.  Orientation of melittin in phospholipid bilayers. A polarized attenuated total reflection infrared study. , 1991, Biophysical journal.

[72]  C. Bucana,et al.  Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes. , 1991, Cancer research.

[73]  J. Barker,et al.  Antibiotic magainins exert cytolytic activity against transformed cell lines through channel formation. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[74]  I. Shalit,et al.  All‐D‐magainin: chirality, antimicrobial activity and proteolytic resistance , 1990, FEBS letters.

[75]  R. B. Merrifield,et al.  All-D amino acid-containing channel-forming antibiotic peptides. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[76]  A. M. van der Bliek,et al.  Multidrug resistance phenotype of human BRO melanoma cells transfected with a wild-type human mdr1 complementary DNA. , 1990, Cancer research.

[77]  R. B. Merrifield,et al.  Binding and action of cecropin and cecropin analogues: antibacterial peptides from insects. , 1988, Biochimica et biophysica acta.

[78]  T. Ganz,et al.  In vitro tumor cell cytolysis mediated by peptide defensins of human and rabbit granulocytes. , 1986, Blood.